SmartFactory is a single-use cGMP bio-manufacturing capacity, which will help Alvotech to rapidly expand its biosimilars business.
Finesse’s customers will also have access to Alvogen’s commercial, FDA approved, biomanufacturing facility.
Alvotech CEO Andreas Herrmann said the partnership allows the company to leverage Finesse’s single-use bio-manufacturing automation platform, combining best-of-breed bio-process equipment from upstream through downstream.
"This strategic relationship provides us with much-needed additional manufacturing capacity and scale-up capabilities which will allow us to expedite our ambitions to become a global leader in the high-growth biopharmaceutical industry," Herrmann said.
"The first manufacturing suite will be in place by the end of 2015."
Finesse CEO Barbara Paldus said Alvotech is capitalizing on the extraordinary flexibility afforded by SmartFactory, and together we will be able to implement cutting-edge, innovative solutions for established and development-stage biosimilars processes.
"The Alvotech facility will showcase our latest SMART technologies in process control, batch automation and data management," Paldus said.
"This partnership will also provide us with an important path to offer full-scale commercial manufacturing to our customers."